Key facts
- It has raised $14.3M; the latest was Later Stage VC ($14.3M) in Feb 2026.
- Notable investors include CICC Capital, Optics Valley Financial Holdings Group, Wuxi AstraZeneca CICC Venture Capital Partnership, Huaxin Capital, Lanhu Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Glycogene
- ·The full record, as it builds
Funding rounds
No funding rounds for Glycogene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glycogene
Manufacturer of glycoscience series products intended to serve the biotechnology industry. The company offers carbohydrate-focused material development, nucleic acid-related material production, and quality-controlled supply processes, enabling biotechnology companies, pharmaceutical developers, and research institutions to advance biological research and accelerate scientific discovery in health-related fields.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2019
- Employees
- 250
- Website
- cn.glycogene.com/
- Ownership
- Privately Held (backing)
Glycogene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glycogene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glycogene in its N-PORT filings yet. We sweep new filings monthly.